references/study_design_canon.md
Study Design Canon
Reference knowledge base for prospective clinical study design. Use this when filling the protocol synopsis and defending design choices at a phase gate.
The estimand-first mindset (ICH E9(R1))
Before choosing an endpoint or a sample size, define the estimand: the precise treatment effect the trial will estimate. ICH E9(R1) defines five attributes — population, treatment, endpoint (variable), intercurrent-event handling strategy, and population-level summary. Skipping the estimand is the most common cause of a trial that "succeeds" statistically but answers the wrong question. Intercurrent events (treatment discontinuation, rescue medication, death) must have a pre-specified strategy (treatment-policy, hypothetical, composite, while-on-treatment, principal-stratum).
Design selection
- Parallel-group RCT — the default for confirmatory efficacy. Two or more arms, randomized, concurrent controls.
- Crossover — each subject is their own control; only valid for chronic, stable, reversible conditions with adequate washout.
- Adaptive designs — pre-planned modifications (sample-size re-estimation, arm dropping, seamless phase 2/3). Powerful but require simulation and regulatory pre-agreement (FDA Adaptive Designs guidance, 2019).
- Single-arm — only defensible with a well-characterized natural history / external control, common in rare disease and oncology early phases.
Randomization & blinding
Randomization removes selection bias; stratify on strong prognostic factors (and always on site in multicenter trials). Blinding (single / double / triple) removes ascertainment and analysis bias. Document the unblinding plan and the DSMB charter for any interim looks.
Multiplicity
Any trial with more than one primary endpoint, more than two arms, or interim analyses inflates the family-wise type-I error. Pre-specify the control strategy: hierarchical (fixed-sequence) testing, Bonferroni / Holm, or a graphical (Bretz-Maurer) approach. The FDA Multiple Endpoints guidance (2022) is the operative reference.
Reporting standards as design checklists
CONSORT 2010 (parallel-group RCT reporting) and SPIRIT 2013 (protocol content) are reporting standards — but used proactively they are design checklists. If you cannot fill a SPIRIT item, the design has a gap.
Sources
- ICH E8(R1), General Considerations for Clinical Studies (2021) — quality-by-design, fit-for-purpose study design.
- ICH E9, Statistical Principles for Clinical Trials (1998) and the E9(R1) Addendum on Estimands and Sensitivity Analysis (2019).
- Schulz, Altman & Moher, CONSORT 2010 Statement — BMJ 2010;340:c332.
- Chan et al., SPIRIT 2013 Statement: defining standard protocol items for clinical trials — Ann Intern Med 2013;158:200-207.
- FDA, Multiple Endpoints in Clinical Trials: Guidance for Industry (2022).
- FDA, Adaptive Designs for Clinical Trials of Drugs and Biologics (2019).
- Friedman, Furberg, DeMets, Fundamentals of Clinical Trials, 5th ed. (Springer, 2015).